NLM’s DailyMed workshop placed structured drug labels at the center of drug data use
The National Library of Medicine used its DailyMed workshop series to push a deceptively simple idea: drug label data becomes far more useful when it is structured, searchable, and tied to a common terminology. The 2014 meeting, titled “SPL/DailyMed Jamboree Workshop 2014 – Practical use of DailyMed and RxNorm Drug Data,” brought together speakers from federal agencies, industry, academia, and nonprofit organizations to discuss how Structured Product Label data and RxNorm can be put to work in real-world settings.
The focus was practical rather than abstract. DailyMed is built around drug product label information, and the workshop emphasized novel ways to use the free data produced cooperatively by NLM and FDA. For clinicians, informaticians, and developers, that cooperation matters because a standard label format is what allows medication information to move cleanly across systems, databases, and applications without losing meaning along the way.
One sentence captures the entire public-health logic of the effort: standardized label data is not a convenience feature, it is infrastructure.
Structured Product Label data gives medication information a usable clinical form
The workshop’s central topic, Structured Product Label data, sits at the intersection of medication safety, regulatory data, and clinical workflow. Traditional drug labels can be difficult to reuse computationally when they remain locked in document form. SPL changes that by organizing drug information into a structured format that software can parse, compare, and display in more useful ways.
That architecture has direct bedside implications. A label that can be queried by indication, dosage form, strength, warnings, or manufacturer is easier to integrate into prescribing tools, medication reconciliation systems, formulary resources, and research platforms. It also helps reduce ambiguity when multiple products share similar names or when a system needs to distinguish one formulation from another.
The workshop framed those possibilities through applied examples rather than theory. Speakers from the federal government, including NLM and IHS, joined colleagues from Bayer, Wolters-Kluwer, and other sectors to share experience with SPL and RxNorm. The broad mix of presenters reflected the reality that drug data problems rarely stay inside one institution.
RxNorm remains the bridge between labels and medication terminology
The companion focus on RxNorm was equally important. RxNorm provides normalized names for clinical drugs and supports consistent medication terminology across systems. In practice, that means a label can be linked more reliably to the way a medication is named, ordered, documented, and analyzed in digital systems.
For drug information specialists, the value lies in interoperability. A label can contain rich product details, but those details become far more useful when they connect to a shared vocabulary that supports search, mapping, and aggregation. That is especially relevant in environments where brand-name products, generics, and over-the-counter medications all need to coexist in the same data ecosystem.
The 2013 DailyMed Jamboree Workshop followed the same path. It was a free public meeting titled “SPL/DailyMed Jamboree Workshop – Using DailyMed Drug Product Label Data,” and it included presenters from the brand name, generic name, and OTC drug industries, along with representatives from the FDA, NLM, and other government agencies. Archived recordings and slides from that meeting are available, extending the workshop’s reach beyond the room in which it was held.
Public archives extend the reach of a specialized data resource
The archived recordings matter because drug data work often advances through implementation rather than headlines. A workshop may last a day, but the label content it addresses is used continuously in clinical software, regulatory review, research tools, and drug information services. Making the material available afterward gives institutions another chance to adapt the content to local needs.
This kind of public archive also supports a wider audience than the original attendees. Health IT developers may use the materials to improve medication databases. Researchers may use them to understand how structured labeling affects data quality. Pharmacy informatics teams may use them to refine product matching or drug knowledge bases. Even where the workshop does not solve every technical problem, it creates a shared reference point for people who need the same medication data to behave consistently across systems.
The FDA SPL work group keeps the literature trail open
The page also points to the FDA Structured Product Label work group bibliography, which maintains a list of publications related to drug product labels and their application in research and practice. That bibliography serves a different but related purpose: it gives users a path into the broader body of literature around SPL and its downstream uses.
For clinicians and informaticians, bibliographies can be more than a convenience. They function as a map of how a data standard has been studied, adopted, and reused. In a field where terminology and format can determine whether medication information is machine-readable, a curated publication list helps users move from concept to implementation without losing the original regulatory context.
The page’s additional links to DailyMed announcements, RSS updates, drug class browsing, label archives, downloadable data, image guidelines, and application development support reinforce the same message. DailyMed is not simply a repository of labels. It is a distribution point for structured medication data, documentation, and technical support material designed for people who need to use the labels in practical settings.
The challenge now is not whether structured labeling has value. The harder task is turning that value into consistent behavior across software, institutions, and data products, where even small differences in terminology or formatting can alter how a medication is found, displayed, or interpreted.
That makes the workshop series more than an archived event. It is a record of how federal drug information infrastructure is being translated into usable clinical and technical tools, one label standard and one shared vocabulary at a time.